Articles

Myovant Sciences Articles

October 21, 2020GlobeNewswirePress Release

Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids

BASEL, Switzerland, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare com... See more »
October 14, 2020Seeking AlphaNews

Relugolix Has Strong Competition

September 30, 2020The Pharma LetterNews

BRIEF-Setback for relugolix in prostate cancer

Myovant Sciences' relugolix failed to achieve statistical superiority for castration resistance-free.... See more »
September 29, 2020NewsFilePress Release

Investigation of Myovant Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - September 29, 2020) - Holzer & Holzer, LLC is investigating wheth... See more »
September 29, 2020Investor’s Business DailyNews

Myovant Sciences Stock Crashes On Poor Trial Data For Prostate Cancer Treatment

Myovant Sciences posted poor trial data for part of a Phase 3 study for a prostate cancer treatment t... See more »
September 29, 2020Endpoints NewsNews

Myovant shows disappointing prostate cancer data on the way to the FDA, stock sinks

Myovant $MYOV has been prepping relugolix for advanced prostate cancer over the last several months, ... See more »
September 23, 2020GlobeNewswirePress Release

Myovant Sciences Launches "Forward for Health Equity" Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

BASEL, Switzerland, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare co... See more »
September 21, 2020Seeking AlphaNews

The Good, Bad And Ugly Of Biopharma

August 24, 2020Pharamceutical TechnologyNews

Oral GnRH antagonists could have market potential in the female infertility space

On 17 August, Myovant Biosciences announced the FDA acceptance of its New Drug Application (NDA) for ... See more »
August 19, 2020The Pharma LetterNews

FDA accepts NDA for relugolix combo for uterine fibroids

Switzerland-based Myovant Sciences (NYSE: MYOV) says that its New Drug Application (NDA) for once-dai... See more »
August 11, 2020NewsOkNews

Fiscal 1Q Earnings Snapshot

LONDON (AP) _ Myovant Sciences Ltd. (MYOV) on Tuesday reported a loss of $32.9 million in its fiscal ... See more »
August 5, 2020BenzingaNews

Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals

USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma to furthe... See more »
June 30, 2020GlobeNewswirePress Release

BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate Cancer

CHICAGO, Ill.; SAN MATEO, Calif.; LOS ANGELES, Calif.; and BASEL, Switzerland, June 30, 2020 (GLOBE N... See more »
June 22, 2020GlobeNewswirePress Release

Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer

BASEL, Switzerland, June 22, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare com... See more »
April 14, 2020centralchartsPress Release

Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health

Initiative to spotlight diverse, personal stories about menstruation in partnership with storytelling... See more »
March 10, 2020centralchartsPress Release

Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020

BASEL, Switzerland, March 10, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare co... See more »
February 10, 2020GlobeNewswirePress Release

Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare com... See more »
October 31, 2019GlobeNewswirePress Release

Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders

BRISBANE, Calif. and BASEL, Switzerland, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MY... See more »
October 21, 2019GlobeNewswirePress Release

Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis

BRISBANE, Calif. and BASEL, Switzerland, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MY... See more »
Loading interface...
Loading interface...
Loading interface...
Loading interface...